V
2.44
0.57 (30.48%)
| Previous Close | 1.87 |
| Open | 1.90 |
| Volume | 12,669,573 |
| Avg. Volume (3M) | 256,226 |
| Market Cap | 6,343,512 |
| Price / Sales | 30.66 |
| Price / Book | 0.670 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -6,184.31% |
| Diluted EPS (TTM) | -1.70 |
| Quarterly Revenue Growth (YOY) | 75.90% |
| Total Debt/Equity (MRQ) | 8.98% |
| Current Ratio (MRQ) | 3.25 |
| Operating Cash Flow (TTM) | -9.46 M |
| Levered Free Cash Flow (TTM) | -5.03 M |
| Return on Assets (TTM) | -75.10% |
| Return on Equity (TTM) | -35.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | VivoSim Labs, Inc. | - | - |
AIStockmoo Score
0.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.00% |
| % Held by Institutions | 6.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Albion Financial Group /Ut | 30 Jun 2025 | 159 |
| Farther Finance Advisors, Llc | 30 Jun 2025 | 58 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |